Sep 15, 2026
Cosmos Health Moves to Tokenize CCX0722 Intellectual Property in Innovative Non-Dilutive Structure, Eyes $562 Billion Weight-Management Market
Cosmos Health Inc. is tokenizing the intellectual property of its weight-management medical device, CCX0722, through a non-dilutive financing structure with Prime Ledger Inc. This initiative aims to fund the device's development without issuing new common stock, leveraging the burgeoning $562 billion weight-management market and the growing $18.9 trillion tokenized real-world-asset market. CCX0722 is an ingestible hydrogel designed to promote satiety, and its patent applications are advanced in major global markets.
Company relevance
100.00%
Company sentiment
Bullish
Overall sentiment
Bullish
Sep 15, 2026
Cosmos Health Adds 5.2 Million Units in New Five-Year Agreements with Target Pharma; Orderbook Surges Past 32.7 Million Units, Up 31% Since June
Cosmos Health Inc.'s subsidiary, Cana Laboratories S.A., has secured new five-year manufacturing agreements with Target Pharma for approximately 5.2 million units, focusing on dermatology and anti-infective products. This boosts Cana's orderbook to over 32.7 million units, a 31% increase since June 2026, and expands its therapeutic coverage to 11 categories. The company expects this growth to contribute to over $10 million in recurring annual profit at full capacity, demonstrating a significant step change in the division's scale.
Company relevance
100.00%
Company sentiment
Bullish
Overall sentiment
Bullish